Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 54

Hims & Hers rolls out unapproved peptides with a massive warning

Hims & Hers launched a Peptides+ platform offering five new compounded peptide and longevity treatments, though the company admits its data on efficacy is still thin. While 10,000 users signed up in just 15 days, health experts and the company’s CMO admit the products are being used without full clinical data.

By the Paparazzi desk Caught by @agus.wijaya72
Catcher · Bronze
November 18, 2026 · 2:02 PM · cnbc.com · 0 views
Fact boxTrust 65/100 · Developing
What we verified
  • Original source: cnbc.com.
  • The source published it on Nov 18, 2026 at 2:02 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Hims & Hers just dropped a Peptides+ platform, rolling out five new compounded peptide and longevity treatments made right here in the U.S. Even with the big debut, the company is already throwing out a caveat: they still have a lot to learn about exactly how these peptides work.

The new lineup includes formulations of sermorelin, glutathione, NAD+, compounded vitamin B-12, and L-carnitine. These powerful, unapproved peptides have already captured massive interest, with over 10,000 people signing up for the early access list within 15 days, according to a company spokesperson.

Sponsored

While Hims confirms its treatments are not yet approved by the FDA, they say they are legally operating through licensed pharmacies that meet high quality standards. The company plans to expand its offerings to include even more unapproved options like BPC-157 and TB-500.

However, Hims Chief Medical Officer Dr. Anant Vinjamoori warned that they lack the typical data seen with established compounds. He stressed that they may need to adjust dosages or refer patients to other care options based on real-world results.

The push by Hims is facing heat from health experts. Chemistry professor Joshua Kritzer cautioned that without large-scale clinical trials, users are relying on anecdotal information—which he says is nowhere near enough to put a substance into your body.

Cell biology professor Paul Knoepfler flagged dosing as a major concern, noting that the 'goosey' nature of these products makes it impossible to know the safest or most effective amounts to use without formal testing, and warns of potential immune responses that could be very bad for one's health.

TopicsHims & Hers · Andrew Huberman · Anant Vinjamoori · Robert F. Kennedy Jr.

Share

Source: cnbc.com

Written by AI from verified reporting.

More stories

  • Health & science 13:42 UTC · 1 hour ago · medicalxpress.com · Caught by @lantern129 · 0 views
    DNA rewires how your cells answer alcohol, nicotine and caffeine
  • Health & science 11:45 UTC · 3 hours ago · hindustantimes.com · 0 views
    ICMR wires up 70 labs into an outbreak early-warning grid
  • Health & science 08:01 UTC · 7 hours ago · theguardian.com · 1 view
    Wellcome puts £9.3m into first major study of UK's under-16 social media ban
  • Health & science 07:13 UTC · 8 hours ago · theguardian.com · Caught by @Crypto fresh · 2 views
    Viagra-Style Pill Slows Alzheimer's Decline by 31% in Global Trial
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.